FINWIRES · TerminalLIVE
FINWIRES

ASX:OCC

6 stories mentioning ASX:OCCUpdated 36d ago

Every FINWIRES story that references ASX:OCC, newest first.

Asia

Orthocell Completes First Commercial Sales of Remplir Nerve Repair Device in Canada

Orthocell (ASX:OCC) has completed first commercial sales of its Remplir nerve repair device in Canada, a milestone in the global rollout of its peripheral nerve reconstruction product, according to a Thursday Australian bourse filing.The company said Remplir is now approved for sale and generating revenue in Australia, New Zealand, the US, Singapore, Hong Kong, and Canada, with expansion planned into the EU and UK markets following expected approval in the second half of calendar 2026.Orthocell held more than AU$48 million in cash as at March 31, with no debt, it added.

ASX:OCC
Asia

Orthocell Says Post-Market Follow-Up Study Shows Overall Treatment Success Rate of Nearly 90% for Nerve Repair Product; Shares Jump 4%

Orthocell (ASX:OCC) said results from an ongoing multi-center post-market clinical follow-up study for its nerve repair product, Remplir, showed an overall treatment success rate of nearly 90%, based on performance data from 66 patients, according to a Tuesday Australian bourse filing.The company said over 90% of motor nerve repairs resulted in functional muscle recovery, while more than 89% of nerve decompression procedures resulted in complete relief or significant improvement of symptoms.The patients were aged 14 to 82 years, and the majority of the procedures were performed in the upper limb. No post-treatment complications or adverse effects were reported.Orthocell's shares jump nearly 4% in recent trading on Tuesday.

ASX:OCC
Asia

Orthocell's Fiscal Year 2026 Revenue Estimate Cut to AU$13.4 Million, Euroz Hartleys Says

Orthocell's (ASX:OCC) fiscal year 2026 revenue is now estimated to reach AU$13.4 million, revised down from AU$14.4 million, Euroz Hartleys said in a note on Tuesday.Orthocell said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir. Its management attributed the flat quarterly revenue growth to seasonality.Euroz Hartleys says that Orthocell has delivered around 8.5% compound quarterly revenue growth over the past 15 quarters.The investment firm maintained its speculative buy recommendation on Orthocell and lowered its price target to AU$1.09 per share from AU$1.19 per share.

ASX:OCC
Asia

Orthocell Says March Quarter Revenue in Line With Prior Quarter; Shares Down 5%

Orthocell (ASX:OCC) said it achieved a revenue of AU$3.2 million in the March quarter, in line with the prior quarter and primarily driven by sales of its nerve repair product, Remplir, according to a Monday Australian bourse filing.The company expects a material uplift in US revenue in the upcoming quarters after the establishment of a commercial distribution platform in the country, with its network expanded to cover over 16 states and around 40% of the population.Regulatory approval for the commercial distribution of Remplir in the US and UK is anticipated in the second half of 2026.Orthocell's shares fell past 5% in recent trading on Monday.

ASX:OCC
Asia

Orthocell Says First Surgical Case Using Nerve Repair Product in US Department of Defense Hospital Network Completed

Orthocell (ASX:OCC) said that a surgery at a military base hospital in Ohio within the US Department of Defense/Veterans Affairs hospital network was the first surgical case using its nerve repair product, Remplir, according to a Friday Australian bourse filing.The company said that this represented an important step in its US commercialization strategy.

ASX:OCC
Asia

Orthocell Wins Approval for Nerve Repair Device Across US Military, VA Hospital Networks

Orthocell (ASX:OCC) said it has secured approval for its Remplir nerve repair device to be used across the US Department of Defense and Veterans Affairs hospital networks, according to a Wednesday Australian bourse filing.The company said it will use its existing US distributor network to target military and VA surgeons operating within these hospital systems, which currently covers 17 states.The approval comes as Orthocell said it is seeing growing evidence of increasing commercialization and revenue momentum in the US market.

ASX:OCC

Track with the FINWIRES app suite

FolioX
FolioX
Track ASX:OCC in your portfolio
WheelAI
WheelAI
Analyze ASX:OCC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on ASX:OCC